Human papillomaviruses target the double-stranded RNA protein kinase pathway

Journal of General Virology

Volumn 87, Issue 11, 2006, Pages 3183-3193

  Hebner, Christy M ^a   Wilson, Regina ^a   Rader, Janet ^b   Bidder, Miri ^b   Laimins, Laimonis A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7; PROTEIN KINASE R; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF2ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EPISOME; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INNATE IMMUNITY; KERATINOCYTE; NONHUMAN; PREPUCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; VESICULAR STOMATITIS VIRUS; VIRUS CULTURE; VIRUS GENOME; VIRUS INFECTION; VIRUS TRANSCRIPTION; WART VIRUS;

ANIMALS; BIOPSY; CELLS, CULTURED; CERVIX UTERI; CYTOPLASMIC STRUCTURES; DOWN-REGULATION; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GENOME, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; MICE; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PHOSPHORYLATION; PROTEIN KINASES; REPRESSOR PROTEINS; RNA, DOUBLE-STRANDED; TRANSCRIPTION, GENETIC; TRANSFECTION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE; VESICULAR STOMATITIS VIRUS;

EID: 33750264663     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.82098-0     Document Type: Article

References (54)

1. Balachandran, S. & Barber, G. N. (2004). Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5, 51-65.
2. Barber, G. N. (2001). Host defense, viruses and apoptosis. Cell Death Differ 8, 113-126.
3. Brierley, M. M. & Fish, E. N. (2002). IFN-α/β receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res 22, 835-845.
4. Burgert, H.-G., Ruzsics, Z., Obermeier, S., Hilgendorf, A., Windheim, M. & Elsing, A. (2002). Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269, 273-318.
5. Chang, Y. E. & Laimins, L. A. (2000). Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74, 4174-4182.
6. Cheng, S., Schmidt-Grimminger, D. C., Murant T., Broker, T. R. & Chow, L. T. (1995). Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 9, 2335-2349.
7. Clemens, M. J. (1997). PKR - a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol 29, 945-949.
8. Cuddihy, A. R., Li, S., Tam, N. W. N., Wong, A. H.-T., Taya, Y., Abraham, N., Bell, J. C. & Koromilas, A. E. (1999a). Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol Cell Biol 19, 2475-2484.
9. Cuddihy, A. R., Wong, A. H.-T., Tam, N. W. N., Li, S. & Koromilas, A. E. (1999b). The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 18, 2690-2702.
10. de Haro, C., Méndez, R. & Santoyo, J. (1996). The eIF-2α kinases and the control of protein synthesis. FASEB J 10, 1378-1387.
11. de Villiers, E.-M. (1994). Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol 186, 1-12.
12. Dyson, N., Howley, P. M., Munger, K. & Harlow, E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937.
13. Elia, A., Laing, K G., Schofield, A., Tilleray, V. J. & Clemens, M. J. (1996). Regulation of the double-stranded RNA-dependent protein kinase PKR by RNAs encoded by a repeated sequence in the Epstein-Barr virus genome. Nucleic Acids Res 24, 4471-4478.
14. Fehrmann, F. & Laimins, L. A. (2003). Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22, 5201-5207.
15. Fehrmann, F., Klumpp, D. J. & Laimins, L. A. (2003). Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J Virol 77, 2819-2831.
16. Frattini, M. G., Lim, H. B. & Laimins, L. A. (1996). In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc Natl Acad Sci U S A 93, 3062-3067.
17. Galloway, D. A. & McDougall, J. K. (1996). The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 7, 309-315.
18. Halbert, C. L., Demers, G. W. & Galloway, D. A. (1991). The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65, 473-478.
19. Hershey, J. W. B. (1991). Translational control in mammalian cells. Annu Rey Biochem 60, 717-755.
20. Howley, P. M. (1996). Papillomavirinae: the viruses and their replication. In Fundamental Virology, 3rd edn, pp. 947-978. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia, PA: Lippincott-Raven.
21. Huibregtse, J. M., Schaffner, M. & Howley, P. M. (1991). A cellular. protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10, 4129-4135.
22. Hummel, M., Hudson, J. B. & Laimins, L. A. (1992). Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J Virol 66, 6070-6080.
23. Kazemi, S., Papadopoulou, S., Li S., Su, Q, Wang, S., Yoshimura, A., Matlashewski, G., Dever, T. E. & Koromilas, A. E. (2004). Control of α subunit of eukaryotic translation initiation factor 2 (eIF2α) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2α-dependent gene expression and cell death. Mol Cell Biol 24, 3415-3429.
24. Longworth, M. S. & Laimins, L. A. (2004). The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 78, 3533-3541.
25. Malmgaard, L. (2004). Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 24, 439-454.
26. 1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol 72, 975-985.
27. Marx, J. (2005). P-bodies mark the spot for controlling protein production. Science 310, 764-765.
28. Meyers, C. & Laimins, L. A. (11994). In vitro systems for the study and propagation of human papillomaviruses. Curr Top Microbiol Immunol 186, 199-215.
29. Miyaji, K., Nakagawa, Y., Matsumoto, K. & 9 other authors (2003). Overexpression of a DEAD box/RNA helicase protein, rck/p54, in human hepatocytes from patients with hepatitis C virus-related chronic hepatitis and its implication in hepatocellular carcinogenesis. J Viral Hepat 10, 241-248.
30. Mohr, I. (2004). Neutralizing innate host defenses to control viral translation in HSV-1 infected cells. Int Rev Immunol 23, 199-220.
31. Monsonego, J., Bosch, F. X., Coursaget P. & 12 other authors (2004). Cervical cancer control, priorities and new directions. Int J Cancer 108, 329-333.
32. Münger, K, Werness, B. A., Dyson, N., Phelps, W. C., Harlow, E. & Howley, P. M. (1989). Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8, 4099-4105.
33. Nakagawa, Y., Morikawa, H., Hirata, I. & 9 other authors (1999). Overexpression of rck/p54, a DEAD box protein, in human colorectal tumours. Br J Cancer 80, 914-917.
34. Nees, M., Geoghegan, J. M., Hyman, T., Frank, S., Miller, L. & Woodworth, C. D. (2001). Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 75, 4283-4296.
35. Nguyen, M., Song, S., Liem, A., Androphy, E., Liu, Y. & Lambert, P. F. (2002). A mutant of human papillomavirus type 16 E6 deficient in binding a-helix partners displays reduced oncogenic potential in vivo. J Virol 76, 13039-13048.
36. Ozbun, M. A. & Meyers, C. (1998). Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b. J Virol 72, 2715-2722.
37. Park, J.-S., Kim, E.-J., Kwon, H.-J., Hwang, E.-S., Namkoong, S.-E. & Um, S.-J. (2000). Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275, 6764-6769.
38. Patel, R. C. & Sen, G. C. (1998). PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 17, 4379-4390.
39. Roizman, B. (1999). HSV gene functions: what have we learned that could be generally applicable to its near and distant cousins? Acta Virol 43, 75-80.
40. Romano, P. R., Garcia-Barrio, M. T., Zhang, X. & 7 other authors (1998). Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2α kinases PKR and GCN2. Mol Cell Biol 18, 2282-2297.
41. Ronco, L. V., Karpova, A. Y., Vidal, M. & Howley, P. M. (1998). Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 12, 2061-2072.
42. Ruesch, M. N. & Laimins, L A. (1998). Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium. Virology 250, 19-29.
43. Scheffner,, M., Werness, B. A., Huibregtse, J. M. Levine, A. J. & Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
44. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
45. Stark G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H. & Schreiber, R. D. (1998). How cells respond to interferons. Annu Rev Biochem 67, 227-264.
46. Taylor, D. R., Lee, S. B., Romano, P. R., Marshak, D. R., Hinnebusch, A. G., Esteban, M. & Mathews, M. B. (1996). Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR. Mol Cell Biol 16, 6295-6302.
47. Thomas, M. C. & Chiang, C.-M. (2005). E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 17, 251-264.
48. Um, S.-J., Rhyu, J.-W., Kim, E.J., Jeon, K.-C., Hwang, E.-S. & Park, J.-S. (2002). Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett 179, 205-212.
49. Werness, B. A., Levine, A. J. & Howley, P. M. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76-79.
50. Williams, B. R. (1999). PKR; a sentinel kinase for cellular stress. Oncogene 18, 6112-6120.
51. Wilson, R., Fehrmann, F. & Laimins, L. A. (2005). Role of the E1 E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J Virol 79, 6732-6740.
52. zur Hausen, H. (1996). Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288, F55-F78.
53. zur Hausen, H. (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2, 342-350.
54. zur Hausen, H. & de Villiers, E.-M. (1994). Human papillomaviruses. Annu Rev Microbiol 48, 427-447.